Tinea corporis

Summary

Tinea corporis (MONDO:0001461) is a disease and 9 clinical trials. Top therapeutic interventions include itraconazole, clotrimazole, and fluconazole. A subtype of dermatophytosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tinea corporis
Mondo ID	MONDO:0001461
DOID	DOID:12179
ICD-10-CM	B35.4
ICD-11	87792802
SNOMED CT	84849002
UMLS	C0040252
MedGen	508197
Is cancer (heuristic)	no

Disease family

This is a subtype of dermatophytosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › tinea infection › dermatophytosis › tinea corporis

Related subtypes (10): tinea barbae, ectothrix infectious disease, endothrix infectious disease, dermatophytosis of groin and perianal area, tinea unguium, tinea profunda, tinea manuum, dermatophytosis of scalp or beard, tinea pedis, Majocchi granuloma

Subtypes (1): tinea imbricata

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	4
PHASE3	2
Not specified	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07342153	PHASE4	RECRUITING	Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
NCT02227290	PHASE4	COMPLETED	Pediatric Subjects With Tinea Corporis
NCT02466867	PHASE4	COMPLETED	An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis
NCT02767947	PHASE4	COMPLETED	Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
NCT01105013	PHASE3	UNKNOWN	Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections
NCT01349998	PHASE3	COMPLETED	Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
NCT05881980	PHASE2/PHASE3	UNKNOWN	Efficacy and Safety of Terbinafine and Itraconazole
NCT07312604	Not specified	RECRUITING	A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis
NCT07428915	Not specified	COMPLETED	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ITRACONAZOLE	4	2
CLOTRIMAZOLE	4	1
FLUCONAZOLE	4	1
NAFTIFINE HYDROCHLORIDE	4	1
TERBINAFINE	4	1
VEHICLE	0	1
HYOSCYAMINE	-1	2